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ABSTRACT
Objectives: Prostate cancer mortality (PCM) in the
USA is among the lowest in the world, whereas PCM in
England is among the highest in Europe. This paper
aims to assess the association of variation in use of
definitive therapy on risk-adjusted PCM in England as
compared with the USA.
Design: Observational study.
Setting: Cancer registry data from England and the
USA.
Participants: Men diagnosed with non-metastatic
prostate cancer (PCa) in England and the USA between
2004 and 2008.
Outcome measures: Competing-risks survival
analyses to estimate subhazard ratios (SHR) of PCM
adjusted for age, ethnicity, year of diagnosis, Gleason
score (GS) and clinical tumour (cT) stage.
Results: 222 163 men were eligible for inclusion.
Compared with American patients, English patients were
more likely to present at an older age (70–79 years:
England 44.2%, USA 29.3%, p<0.001), with higher
tumour stage (cT3-T4: England 25.1%, USA 8.6%,
p<0.001) and higher GS (GS 8–10: England 20.7%,
USA 11.2%, p<0.001). They were also less likely to
receive definitive therapy (England 38%, USA 77%,
p<0.001).
English patients were more likely to die of PCa
(SHR=1.9, 95% CI 1.7 to 2.0, p<0.001). However, this
difference was no longer statistically significant when
also adjusted for use of definitive therapy (SHR=1.0,
95% CI 1.0 to 1.1, p=0.3).
Conclusions: Risk-adjusted PCM is significantly
higher in England compared with the USA. This
difference may be explained by less frequent use of
definitive therapy in England.
BACKGROUND
Outcomes following a diagnosis of cancer vary
markedly around the world. In the USA,
cancer-related deaths have been demonstrated
to be among the lowest. For example, US
breast cancer mortality is 65% lower than the
European average while death from colorectal
cancer is 30% lower.1 On the other hand,
cancer mortality rates in England are among
the highest in Europe.2 The disparity in
cancer outcomes appears greatest for prostate
cancer (PCa) for which 5-year mortality has
been reported to be six times higher in
England compared with the USA.1
A number of disease and treatment-related
factors may account for the observed vari-
ation in PCa outcomes between the USA and
England. These include variation in policy
concerning PCa screening between the two
countries together with variation in use of
deﬁnitive PCa therapy. Other factors that
may be at play include the methods by which
data on cancer diagnoses and cancer-related
deaths are both collected and processed.
In the USA, the vast majority of men diag-
nosed with localised PCa have deﬁnitive
therapy, either by radical radiation therapy or
radical surgery. For example, three-quarters of
men diagnosed with PCa between 1988 and
2006 were reported to have undergone deﬁni-
tive therapy for their disease.3 This ﬁgure com-
pares to only about one-third in England.4 5
We report differences in risk-adjusted pros-
tate cancer mortality (PCM) between the
USA and England. Furthermore, we investi-
gate whether PCa outcomes are related to the
use of deﬁnitive therapy between the two
countries. This study is part of a programme
of work assessing the value of procedure-
speciﬁc and disease-speciﬁc metrics derived
from English hospital admission records to
Strengths and limitations of this study
▪ A key strength of this paper is the use of rou-
tinely collected data from hospital episode statis-
tics linked to cancer registry data, providing a
large data set to make accurate estimates of rela-
tive prostate cancer mortality.
▪ Lack of prostate-specific antigen data and a rela-
tively short follow-up period of 6 years are the
key limitations of this study.
▪ Given that this is an observational study, there is
some uncertainty about the causes for the
observed differences in prostate cancer mortality.
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assess the performance of English National Health
Service (NHS) providers.
METHODS
Study design
We performed a population-based observational cohort
study using patient-level cancer registry data from
England and the USA.
Data sources
Data collected by the eight regional cancer registries6
for all men diagnosed with PCa in England were linked
to the Hospital Episodes Statistics (HES) database7 and
national mortality records provided by the Ofﬁce for
National Statistics.
The Surveillance, Epidemiology and End Results
(SEER) database was used to identify American patients
with PCa from 18 regional cancer registries.8 This data-
base covers 28% of the US population and is linked to
mortality data provided by the National Center for
Health Statistics.
Participants
Men diagnosed with PCa between 2004 and 2008, and
aged between 35 and 80 years at the time of diagnosis
were identiﬁed from both countries. The years 2004–
2008 were selected as comparable English, and
American data were available for this period. Diagnosis
of PCa was conﬁrmed using the ‘C61’ International
Classiﬁcation of Diseases (ICD-10) diagnosis code in the
HES and SEER databases. Follow-up data were available
through to 16 April 2010 for the English cohort, and
31 December 2010 for the American cohort.
Patients were included if PCa was histologically con-
ﬁrmed as their only primary malignancy. Patients with
lymph node involvement or distant metastases were
excluded, as they would not be candidates for primary
deﬁnitive therapy. Where data on metastatic disease were
missing, we considered the use of chemotherapy as a sur-
rogate marker for metastases. Patients who underwent
chemotherapy within 6 months of diagnosis were there-
fore also excluded. Twenty-one patients in the English
data set were noted to have negative survival data (ie, date
of diagnosis was chronologically after the date of death),
and were therefore excluded. Those with missing data con-
cerning pathological Gleason score (GS) or clinical
tumour (cT) stage were excluded from the primary ana-
lysis, as they would not be amenable to risk stratiﬁcation.
Variable definition
English patients were considered to have undergone
deﬁnitive therapy if their HES record contained the
‘M61’ Ofﬁce of Population Censuses and Surveys
Classiﬁcation of Surgical Operations and Procedures
(4th revision) code9 indicating radical prostatectomy
within 1 year of diagnosis, or alternatively if their cancer
registry record indicated the use of radiotherapy.
Patients from the SEER data set were considered to
have undergone deﬁnitive therapy if they underwent
radical prostatectomy or radiation therapy as part of
their ﬁrst course of therapy. American patients were con-
sidered to have undergone radical prostatectomy if they
had undergone cancer-directed surgery, coded as any of
the following: radical/total prostatectomy, or prostatec-
tomy with resection in continuity with other organs/
pelvic exenteration. All forms of radiotherapy were
assumed to be deﬁnitive in nature, as treatment doses
are not routinely recorded in the SEER or English
cancer registries.
Risk stratification
Patients were classiﬁed into risk groups using a modiﬁed
version of the National Comprehensive Cancer Network
(NCCN) PCa risk classiﬁcation,10 based on cT stage and
GS. Risk groups were deﬁned as follows: low risk (cT1
stage and GS 2–6), intermediate risk (cT2 stage or
GS 7), and high risk (cT3-T4 stage or GS 8–10). Since
prostate-speciﬁc antigen (PSA) levels are not recorded
in the HES database or English cancer registries, this
variable was not used for risk stratiﬁcation in this study.
Outcome measurement
The cause of death among English patients was
extracted from national mortality records provided by
the Ofﬁce for National Statistics, which were linked to
cancer registry and HES data. Similarly, cause of death is
routinely recorded as part of the SEER data set for US
patients. Where the cause of death was listed as the
disease code for PCa, C61, it was classiﬁed as a PCa
death.
Statistical analysis
χ2 test was used to compare proportions between the two
countries. A Cox regression model was used to calculate
adjusted HRs for all-cause mortality (ACM), comparing
mortality in England and the USA. Similarly, adjusted
subhazard ratios (SHR) were calculated for PCM using a
maximum likelihood competing risk regression model,
according to the method of Fine and Gray.11 Failure
event for PCM was deﬁned as death due to PCa, while
death due to a cause other than PCa was deﬁned as the
competing event. All analyses were performed using
STATAV.11 (StataCorp, College Station, Texas, USA).
All regression models were adjusted for age group,
year of diagnosis, ethnicity, cT stage and GS (model 1).
Next, the impact of variation in use of deﬁnitive therapy
was assessed by additionally including use of deﬁnitive
therapy in a separate regression model (model 2).
Separate regression models were built to test for differ-
ences between the two countries for each individual risk
group. This resulted in 20 regression models in total: 5
patient groups (all eligible patients, all patients with
complete data, low, intermediate and high risk)×2 adjust-
ment models (model 1 and model 2)×2 outcomes (ACM
and PCM).
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Sensitivity analysis
In order to investigate the inﬂuence of excluding
patients for whom tumour stage and Gleason grade data
were missing, we performed a sensitivity analysis where
all eligible patients were included.
Role of funding source
The study beneﬁted from a grant from the Academy of
Medical Royal Colleges supporting a project assessing the
value of procedure-speciﬁc and disease-speciﬁc metrics
derived from routinely collected data to assess the perform-
ance of NHS providers. Sponsors were not involved in the
study design; the collection, analysis or interpretation of
data; in the writing of the report; or in the decision to
submit the paper for publication.
RESULTS
Participants
Data were available on 328 182 men (111 917
from England and 216 265 from the USA) of which
301 989 (97 079 from England and 204 910 from the
USA) met the selection criteria. Reasons for exclusion
are described in ﬁgure 1.
Complete data to enable risk stratiﬁcation (ie, cT stage
and GS) were available for 222 163 men (23 235 from
England and 196 928 from the USA). These data were
used to undertake the primary analysis.
Men diagnosed with PCa in England tended to be
older and less ethnically diverse, to present with higher
cT stage, and to have higher pathological GSs (table 1,
see online supplementary appendix 1), with each of
these differences reaching statistical signiﬁcance at
p<0.001. Among patients for whom complete data were
available, men diagnosed with PCa in England were
more likely to present with high-risk PCa according to
our modiﬁed NCCN criteria (34.5% in England and
17.2% in USA, table 1).
Men diagnosed with PCa in England were less likely to
receive deﬁnitive therapy (38.2% in England and 77.1%
in USA), and this difference was observed in all risk
groups (table 1).
Mortality
The median follow-up for the entire cohort was
43.3 months. Unadjusted 6-year ACM among English men
was higher compared with American men (21.0% vs
9.6%). Similarly, unadjusted 6-year PCM among English
men was also higher, as compared with American men
(9.6% vs 2.6%). This trend was similar among patients
with complete data, whose outcomes are described below
(table 2 and ﬁgure 2).
Primary analysis
The primary analysis was conducted using data from the
222 163 patients for whom cT stage and GS were avail-
able, to allow risk stratiﬁcation.
Unadjusted 6-year ACM among patients who had
deﬁnitive therapy was 7.3% in England and 4.9% in the
USA. Corresponding ACM ﬁgures among those who did
not have deﬁnitive treatment were 19.5% in England and
15.5% in the USA. The greatest difference was observed
in patients at high PCa risk undergoing deﬁnitive treat-
ment with a 6-year ACM of 15.1% in England and 8.1%
in the USA, with the smallest difference observed in
patients with low-risk PCa who did not undergo deﬁnitive
therapy (9.5% in England and 9.9% in the USA).
Unadjusted 6-year PCM among patients from all risk
groups who underwent deﬁnitive therapy was 2.4% in
England and 1.2% in the USA. This compared with 8.8%
among patients who did not receive deﬁnitive therapy in
England and 4.5% in the USA. Differences in unadjusted
6-year PCM were smallest among patients with low-risk
disease undergoing deﬁnitive therapy (0.4% in England
and 0.5% in the USA), and greatest among patients with
high-risk disease undergoing deﬁnitive therapy (7.6% in
England and 3.7% in the USA).
When comparing all patients with complete data
amenable for risk stratiﬁcation, following adjustment for
age group, ethnicity, year of diagnosis and tumour
characteristics (model 1), signiﬁcantly higher ACM
(adjusted HR=1.60, 95% CI 1.52 to 1.68) and PCM
(adjusted SHR=1.88, 95% CI 1.72 to 2.05) were found in
England than in the USA (table 2). Within each of the
three risk groups, with adjustment for patient and
tumour characteristics (model 1), the greatest difference
in ACM and PCM was noted among the intermediate-
risk and high-risk patients (table 2). PCM was not signiﬁ-
cantly different at 0.9% in both countries at 6 years
among men with low-risk disease.
When treatment allocation was included in the multi-
variate model (model 2), no difference in ACM and
PCM was noted between the USA and England for all
men (ACM: adjusted HR=1.03, 95% CI 0.97 to 1.08;
PCM: adjusted SHR=0.97, 95% CI 0.88 to 1.07) or
within each of the individual risk groups (table 2).
Sensitivity analysis
Multivariate analysis for the entire cohort of 301 989
patients, including patients for whom data regarding
either cT stage or GS were missing, revealed a similar
trend (see online supplementary appendix 2).
Adjustment for age group, ethnicity and year of diagno-
sis revealed higher ACM (adjusted HR=2.19, 95% CI
2.13 to 2.26) and PCM (adjusted SHR=3.67, 95% CI 3.50
to 3.85) among English patients.
Additional adjustment for the use of deﬁnitive therapy
appeared, in part, to account for variation in ACM
(adjusted HR=1.55, 95% CI 1.50 to 1.59) and PCM
(adjusted HR=2.37, 95% CI 2.25 to 2.50).
DISCUSSION
PCa death in intermediate to high-risk cases is higher in
England than it is in the USA. When we adjusted for the
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different rates of deﬁnitive therapy in the two countries,
the rates of PCa death were similar. This suggests that
the differences in mortality may be explained by a lower
use of deﬁnitive therapy in England.
Methodological considerations
First, the English data set contained a high proportion
of missing data for cT stage and GS. The high propor-
tion of patients with missing data in the English data set
may be due to poor data capture. Excluded English
patients tended to be older, to have more advanced
disease, and they less frequently received deﬁnitive
therapy (see online supplementary appendix 3). This
limitation is unlikely to have had a marked inﬂuence on
our results, as inclusion of these patients would have
increased the observed difference in PCM noted
between the two countries. Thus, these data provide a
conservative estimate of the spread of PCa risk among
the general English population. Nevertheless, it is worth-
while to note that these are the only population-wide
data currently available for comparing management of
PCa in the two countries.
Furthermore, a sensitivity analysis was performed to
investigate the inﬂuence of excluding patients with
missing cT stage or GS. This showed that PCM is signiﬁ-
cantly higher in England than the USA, though this dif-
ference is partly explained on additional adjustment for
the variation in use of deﬁnitive treatment in the two
countries. Owing to the higher proportion of men with
low-risk or intermediate-risk disease in the USA, the
Figure 1 Study flow diagram (HES, Hospital Episodes Statistics; SEER, Surveillance, Epidemiology and End Results).
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variation in use of deﬁnitive treatment becomes more
apparent on risk stratiﬁcation in our primary analysis.
Second, the SEER data set did not contain informa-
tion concerning patient comorbidity. We feel our ﬁnd-
ings remain valid despite this potential limitation as
PCM is less strongly inﬂuenced by comorbid conditions
than ACM.12 In addition, there were also differences
between England and the USA in the PCM of young
patients aged between 35 and 59 years who are least
likely to have comorbid conditions at the time of diag-
nosis (adjusted SHR=2.66, 95% CI 1.99 to 3.56,
p<0.001).
Third, ‘lead time bias’ could be an explanation for
PCM being lower in the USA than in the UK given that
the uptake of PSA testing is much higher in the USA,
the effect of which is likely to be that men in the USA
are diagnosed with less advanced PCa at an earlier age.
In an attempt to minimise the effect of this limitation,
we adjusted for clinical stage at diagnosis and patient
age at diagnosis together with GS in our primary
analysis.
Lastly, PSA levels were not available for English
patients, and therefore they could not be used to adjust
the differences in PCM between England and the USA.
Table 1 Patient demographics by country (n=222 163)
England USA
p Value(n=25 235) (n=196 928)
Year of diagnosis (%)
2004 5378 (21.3) 36 172 (18.4) <0.001
2005 4959 (19.7) 34 403 (17.5)
2006 5172 (20.5) 40 531 (20.6)
2007 5009 (19.9) 43 800 (22.2)
2008 4717 (18.7) 42 022 (21.3)
Age group (%)
35–59 3620 (14.4) 56 399 (28.6) <0.001
60–64 4361 (17.3) 40 287 (20.5)
65–69 6104 (24.2) 42 439 (21.6)
70–74 6145 (24.4) 33 912 (17.2)
75–79 5005 (19.8) 23 891 (12.1)
Ethnicity (%)
White 17 924 (94.8) 154 077 (80.4) <0.001
African/Caribbean 571 (3.0) 28 361 (14.8)
Asian 318 (1.7) 8638 (4.5)
Other 105 (0.6) 626 (0.3)
Missing 6317 5226
cT stage (%)
cT1 9374 (37.2) 72 407 (36.8) <0.001
cT2 9538 (37.8) 107 762 (54.7)
cT3 5577 (22.1) 15 482 (7.9)
cT4 746 (3.0) 1277 (0.7)
Gleason score (%)
2–6 10 909 (43.2) 99 661 (50.6) <0.001
7 9112 (36.1) 75 247 (38.2)
8–10 5214 (20.7) 22 020 (11.2)
Modified NCCN risk (%)
Low risk 6151 (24.4) 45 045 (22.9) <0.001
Intermediate risk 10 386 (41.2) 118 074 (60.0)
High risk 8698 (34.5) 33 809 (17.1)
Treatment—all risk groups (%)
No definitive therapy 15 583 (61.8) 45 113 (22.9) <0.001
Definitive therapy 9652 (38.2) 151 815 (77.1)
Treatment—low risk (%)
No definitive therapy 3799 (61.8) 17 516 (38.9) <0.001
Definitive therapy 2352 (38.2) 27 529 (61.1)
Treatment—intermediate risk (%)
No definitive therapy 5696 (54.8) 21 999 (18.6) <0.001
Definitive therapy 4690 (45.2) 96 075 (81.4)
Treatment—high risk (%)
No definitive therapy 6088 (70.0) 5598 (16.6) <0.001
Definitive therapy 2610 (30.0) 28 211 (83.4)
cT, clinical tumour; NCCN, National Comprehensive Cancer Network.
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To investigate this limitation further, we evaluated if the
inclusion of PSA into our risk stratiﬁcation model
resulted in signiﬁcant recategorisation of a patient’s PCa
risk for the US patients. We found little movement
between risk groups with, for example, only 7.4% US
patients being reclassiﬁed as intermediate-risk having ini-
tially been assigned a low-risk status. Furthermore, Elliott
et al13 have previously shown that while it is advanta-
geous to have all three clinical variables (including PSA,
cT stage and GS) available for risk stratiﬁcation, patients
with high-risk disease can still be correctly identiﬁed
even if one of these variable (such as PSA) is missing.
Despite the aforementioned limitations, routinely col-
lected data provide a rich resource to explain perform-
ance of healthcare providers in different countries.
However, differences in coding practices and differences
in healthcare frameworks must be acknowledged.
Comparison with other studies
Mortality
PCM was found to be signiﬁcantly higher in England
compared with the USA among men with intermediate-
risk and high-risk PCa. In the current study, we used
SEER data of men diagnosed between 2004 and 2008
and found that 6-year ACM was 9.3% and PCM 2.4%.
A study using SEER data of men diagnosed between
1992 and 2005 found very similar ﬁgures (5-year ACM
14.3% and PCM 1.7%).14 Improvements in management
of PCa and other comorbidities may explain why our
ﬁgures for ACM are slightly lower.
In comparison, our analysis of the English HES data-
base found that 6-year ACM was 18.5% and PCM 7.6%.
A study reporting outcome of 50 066 men diagnosed
with PCa in the London area between 1997 and 2006
with a median follow-up of 3.5 years reported a PCM for
men who had undergone deﬁnitive treatment of about
2%, which corresponds closely to the ﬁgures we found
in this study.15
The only two relevant randomised controlled
trials16 17 demonstrated beneﬁt of deﬁnitive therapy in
patients with high-risk disease, which is consistent with
the results of our study.
Differences between England and the USA
A study using the EUROCARE and SEER registries
including men diagnosed between 1985 and 1989
reported a 2.8 times relative excess risk of death among
European men with PCa compared with their American
counterparts.18 A recent study using SEER data between
1975 and 2004 together with UK cancer mortality statis-
tics found that age-adjusted PCM rates in the USA were
signiﬁcantly lower than in England with the decline in
PCM being 4.2% per year since the 1990s, a ﬁgure
about four times higher than that reported for
England.19
The investigators of both these studies suggested that
difference in PCM between England and the USA is the
result of variation in disease burden brought about by
the higher incidence of PCa screening in the USA.
However, neither study adjusted for PCa risk. In this
study, we have identiﬁed for the ﬁrst time that irrespect-
ive of PCa stage and GS, PCa outcomes in terms of ACM
and PCM are better in the USA than in England, which
does not support the increased use of PCa screening in
the USA as an explanation for the difference in PCM.
Instead, our data suggest that the better PCa outcome
Table 2 ACM and PCM according to country of treatment and modified NCCN risk (n=222 163)
6-year ACM
Model 1 (age at diagnosis,
year of diagnosis, ethnicity,
clinical tumour stage and
Gleason score)
Model 2 (model 1 and
definitive therapy)
Risk group USA England Adj HR (95% CI) p Value Adj HR (95% CI) p Value
n=196 928 n=25 235
All risk groups 9.3% 18.5% 1.60 (1.52 to 1.68) <0.001 1.03 (0.97 to 1.08) 0.336
Low risk 8.7% 10.3% 1.30 (1.15 to 1.48) <0.001 1.06 (0.93 to 1.21) 0.397
Intermediate risk 7.6% 12.5% 1.44 (1.32 to 1.58) <0.001 0.98 (0.90 to 1.08) 0.740
High risk 16.3% 31.8% 1.92 (1.78 to 2.06) <0.001 0.99 (0.92 to 1.08) 0.863
6-year PCM
Model 1 (age at diagnosis, year
of diagnosis, ethnicity, clinical
tumour stage and Gleason
score)
Model 2 (model 1 and
definitive therapy)
Risk group USA England Adj SHR (95% CI) p Value Adj SHR (95% CI) p Value
All risk groups 2.4% 7.6% 1.88 (1.72 to 2.05) <0.001 0.97 (0.88 to 1.07) 0.568
Low risk 0.9% 0.9% 1.57 (1.08 to 2.30) 0.018 1.31 (0.89 to 1.93) 0.169
Intermediate risk 1.4% 2.8% 1.71 (1.40 to 2.09) <0.001 1.00 (0.81 to 1.23) 0.994
High risk 8.1% 18.8% 2.06 (1.87 to 2.28) <0.001 0.96 (0.86 to 1.08) 0.537
ACM, all-cause mortality; Adj HR, adjusted HR; Adj SHR, adjusted subhazard ratios; NCCN, National Comprehensive Cancer Network; PCM,
prostate cancer mortality.
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seen in the USA may be due to the more frequent use
of deﬁnitive treatment.
Clinical implication
The decision to offer deﬁnitive PCa therapy is inﬂu-
enced by both disease characteristics and patient
characteristics. As noted in our results, variations in
healthcare systems have direct and indirect effects on
both these factors. The expected survival beneﬁt of
deﬁnitive PCa therapy must therefore also be balanced
against the associated probability of side effects, includ-
ing urinary incontinence and erectile dysfunction.
Our analysis suggests that PCM in England may be
improved by an increase in the use of deﬁnitive treat-
ment. However, due to the retrospective nature of this
analysis, there could be other factors such as lead time
bias which account for this difference. Only randomised
trials can address these differences directly.
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